- |||||||||| OPN-7486 / Opna Bio
Trial completion date, Trial termination, Metastases: Phase 1 Study of PLX7486 as Single Agent in Patients With Advanced Solid Tumors (clinicaltrials.gov) - Mar 21, 2018 P1, N=59, Terminated, Phase classification: P=N/A --> P1 | Recruiting --> Terminated; The study was terminated per PI decision. Trial completion date: Dec 2018 --> Jan 2018 | Active, not recruiting --> Terminated; Discontinued
- |||||||||| OPN-7486 / Opna Bio
Enrollment closed, Enrollment change, Trial primary completion date, Metastases: Phase 1 Study of PLX7486 as Single Agent in Patients With Advanced Solid Tumors (clinicaltrials.gov) - Sep 25, 2017 P1, N=59, Active, not recruiting, Trial primary completion date: Oct 2017 --> Jan 2018 Recruiting --> Active, not recruiting | N=90 --> 59 | Trial primary completion date: Feb 2021 --> Dec 2018 | Recruiting --> Active, not recruiting | N=90 --> 59 | Trial primary completion date: Feb 2021 --> Dec 2018
- |||||||||| AC708 / Daiichi Sankyo
Enrollment closed, Metastases: A Study of PLX73086 in Advanced Solid Tumors and Locally Advanced or Refractory Tenosynovial Giant Cell Tumor (clinicaltrials.gov) - Aug 2, 2017 P1, N=66, Active, not recruiting, Recruiting --> Active, not recruiting | N=90 --> 59 | Trial primary completion date: Feb 2021 --> Dec 2018 | Recruiting --> Active, not recruiting | N=90 --> 59 | Trial primary completion date: Feb 2021 --> Dec 2018 Recruiting --> Active, not recruiting | Trial primary completion date: Feb 2019 --> Oct 2017 | Recruiting --> Active, not recruiting
- |||||||||| dasatinib / Generic mfg.
Trial primary completion date, Metastases: Trial of Dasatinib in Advanced Sarcomas (clinicaltrials.gov) - Oct 13, 2016 P2, N=386, Active, not recruiting, Recruiting --> Active, not recruiting | Trial primary completion date: Feb 2019 --> Oct 2017 | Recruiting --> Active, not recruiting Trial primary completion date: Jun 2015 --> Dec 2016
- |||||||||| dasatinib / Generic mfg.
Enrollment change, Trial primary completion date, Metastases: Trial of Dasatinib in Advanced Sarcomas (clinicaltrials.gov) - Dec 19, 2014 P2, N=386, Active, not recruiting, Trial primary completion date: Dec 2014 --> Mar 2017 N=502 --> 386 | Trial primary completion date: Dec 2014 --> Jun 2015
- |||||||||| dasatinib / Generic mfg.
Trial primary completion date, Metastases: Trial of Dasatinib in Advanced Sarcomas (clinicaltrials.gov) - Jun 19, 2014 P2, N=502, Active, not recruiting, N=502 --> 386 | Trial primary completion date: Dec 2014 --> Jun 2015 Trial primary completion date: Dec 2013 --> Dec 2014
|